Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-157 Taxol
0.00031623
Chemo
Chemotherapy
 1.0667 0.01003
MDA-MB-157 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9388 0.00482
HCC1806 Volasertib
0.00031623
PLK
Cell cycle
 1.0541 -0.00368
MDA-MB-157 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9547 0.00231
MCF 10A INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9954 -0.00126
MCF 10A Palbociclib
0.00031623
CDK4/6
Cell cycle
 1.0029 0.00075
MDA-MB-231 Luminespib
0.00031623
HSP90
Misc
 0.9649 0.00301
MDA-MB-157 Volasertib
0.00031623
PLK
Cell cycle
 1.0814 -0.00135
MDA-MB-134-VI Neratinib
0.00031623
EGFR/HER2
RTK
 1.3354 0.00352
HCC1806 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.8966 0.00900
MDA-MB-157 Palbociclib
0.00031623
CDK4/6
Cell cycle
 0.9482 0.00160
MDA-MB-157 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0129 0.00004
MDA-MB-157 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9745 -0.00090
MDA-MB-134-VI INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9671 -0.00323
MDA-MB-157 Dinaciclib
0.00031623
pan CDK
Cell cycle
 1.0629 -0.00194
MDA-MB-231 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 0.9887 0.00258
HCC1806 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0684 0.00476
MDA-MB-361 Volasertib
0.00031623
PLK
Cell cycle
 1.1354 -0.00403
MCF 10A Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 0.9969 -0.00072
MDA-MB-231 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9574 0.01575
MDA-MB-361 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9582 0.00538
MDA-MB-361 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0304 0.00017
MCF 10A Neratinib
0.00031623
EGFR/HER2
RTK
 1.0022 -0.00084
SK-BR-3 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9595 -0.00239
HCC1806 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9295 0.00552